Long-term outcome in pulmonary arterial hypertension: A plea for earlier parenteral prostacyclin therapy

European Respiratory Review

Volumn 18, Issue 114, 2009, Pages 253-259

  Delcroix, M ^a   Spaas, K ^a   Quarck, R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Endothelin receptor antagonists; Outcome; Prostacyclin analogues; Pulmonary arterial hypertension

Indexed keywords

BERAPROST; BOSENTAN; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ADD ON THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; EXPERIENCE; FUNCTION TEST; HEALTH CENTER; HEART RIGHT VENTRICLE FAILURE; HUMAN; INFORMATION; INJECTION SITE PAIN; LUNG CIRCULATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTOR VARIABLE; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL; SURVIVAL TIME;

EID: 73449084124     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00003109     Document Type: Review

References (29)

1. D'Alonzo G, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991; 115: 343-349.
2. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
3. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
4. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
6. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007; 132: 757-763.
7. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
8. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
9. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
10. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491.
11. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132: 373-379.
12. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report - 2008. J Heart Lung Transplant 2008; 27: 957-969.
13. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203.
14. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129: 1636-1643.
15. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005; 26: 1895-1902.
16. Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009; 34: 132-137.
17. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249.
18. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
19. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
20. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304.
21. Rich S, Kaufmann E, Levy PS. The effects of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
22. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
23. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit CareMed 2002; 165: 800-804.
24. Arneson C. Prognostic Factors Associated with Survival in 860 PAH Patients Treated With Subcutaneous Treprostinil Over a 3 Year Period. Pulmonary Hypertension Association Congress, 2008. www. phassociation.org/Medical/ articles/SS2008/1045-Arneson,Carl.pdf Date last updated: June 22, 2008. Date last accessed: May 27, 2009.
25. Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001; 20: 262-263.
26. Tankersley MA, D'Albini LD, Ozanich AN, et al. A 36-month Survival Analysis of Patients Beginning Oral PAH Monotherapy: An Indication for Escalation of Therapy? Pulmonary Hypertension Association Congress, 2008. www.phassociation.org/Medical/ articles/SS2008/1062-Tankersley,Mark.pdf Date last updated: June 22, 2008. Date last accessed: May 27, 2009.
27. Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001; 138: 287-297.
28. Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211-1218.
29. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.